On Wednesday, Loop Capital reiterated its Buy rating on Ardent Health Partners Inc (NYSE:ARDT) with a steady price target of $21.00. The firm's analyst, while adjusting valuation methods and updating estimates, has lowered the EBITDA forecast for the fourth quarter to align with the expectations set by the company's management.
Despite this revision, the analyst expressed confidence in Ardent Health's potential to capitalize on the recent expansion of the New Mexico DPP program, which was approved by CMS in December.
The analyst at Loop Capital has refined the valuation approach for Ardent Health by introducing a discounted cash flow (DCF) model. This change is part of the firm's ongoing efforts to provide a more accurate valuation of the company's stock. The DCF model is a valuation method used to estimate the value of an investment based on its expected future cash flows.
Ardent Health's position to benefit from the retroactive aspect of the New Mexico DPP program expansion is a key point in the analyst's outlook. This program's expansion could provide additional revenue streams for the company, which is a positive indicator for investors considering the company's prospects.
In other recent news, Ardent Health Partners has been the subject of several analyst reviews and operational adjustments. BofA Securities recently downgraded Ardent Health from Buy to Neutral due to potential risks to the company's financial outlook stemming from the recent election's impact on healthcare policy. They also reduced their price target for the company to $19, based on a lower multiple of the estimated 2025 EBITDAR.
Several analyst firms have provided their views on these recent developments. KeyBanc Capital Markets initiated coverage on Ardent Health with an Overweight rating, while Stephens maintained its Overweight rating for the company. Truist Securities raised its price target on Ardent Health shares, and Morgan Stanley (NYSE:MS) also assigned an Overweight rating to the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.